2. JAK/STAT Signaling Protein Tyrosine Kinase/RTK
  3. EGFR
  4. Depatuxizumab

Depatuxizumab  (Synonyms: ABT-806)

目录号: HY-P99849 纯度: 99.58%
COA

摩尔计算器

Depatuxizumab 是一种可透过血脑屏障 (brain-penetrant) 的人源化肿瘤特异性抗 EGFR 的单克隆抗体。Depatuxizumab 抑制突变型 EGFRvIII 和野生型 EGFR 异种移植瘤模型的生长。Depatuxizumab 可用于癌症研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Depatuxizumab Chemical Structure

Depatuxizumab Chemical Structure

CAS No. : 1471999-69-5

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥3200
In-stock
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Customer Review

Depatuxizumab 相关抗体

Top Publications Citing Use of Products

查看 EGFR 亚型特异性产品:

查看所有亚型
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer[1].

同型

Human IgG1 kappa
推荐同型对照抗体
种属

Chimeric; Humanized
体内研究
(In Vivo)

Depatuxizumab (10， 40 mg/kg， i.p.， 每周3次， 持续2周) 在 Nu/Nu 小鼠的 U87MGde2-7 多形性胶质母细胞瘤 (GBM) 模型和 A431 鳞状荷瘤模型中显著抑制肿瘤生长[1]。
Depatuxizumab (10， 40 mg/kg， i.p.， 每周3次， 持续2周) 在 NSG 小鼠的 EGFRvIII 阳性 GBM-SN0199-PDX 模型中抑制肿瘤生长和 pEGFR 水平[1]。
Depatuxizumab (2-40 mg/kg， i.p.， 每周三次， 持续2周) 在 SCID Beige 小鼠的 SCC15 荷瘤模型中以剂量依赖方式抑制肿瘤生长[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: U87MGde2-7 glioblastoma multiforme (GBM) model of Nu/Nu mice[1]
Dosage: 10, 40 mg/kg, three times a week for 2 weeks
Administration: Intraperitoneal injection (i.p.)
Result: Inhibited tumor growth significantly more than Cetuximab (HY-P9905).
Promoted a significant increase in TGI (tumor growth inhibition) when it combined with Temozolomide (HY-17364).
Animal Model: EGFRvIII-positive GBM SN0199 PDX model, 3 to 5 mm3 passage 3 (P3) tumor fragments were s.c. trochar implanted in the right rear flank of NSG mice[1]
Dosage: 10, 40 mg/kg, three times a week for 2 weeks
Administration: Intraperitoneal injection (i.p.)
Result: Inhibited tumor growth significantly and reduced levels of pEGFR.
Animal Model: A431 squamous xenograft model of Nu/Nu mice[1]
Dosage: 10, 40 mg/kg, three times a week for 2 weeks
Administration: Intraperitoneal injection (i.p.)
Result: Inhibited tumor growth with comparable activity to Cetuximab (HY-P9905) dosed in an equivalent manner at 10 mg/kg.
Inhibited tumor growth by 58% at 40 mg/kg.
Animal Model: SCC15 xenograft model of SCID Beige mice[1]
Dosage: 2, 10, 20, 40 mg/kg, three times a week for 2 weeks
Administration: Intraperitoneal injection (i.p.)
Result: Inhibited tumor growth with dose manner.
Reduced the level of pEGFR and total EGFR in time-dependent.
Reduced cell proliferation as measured by phospho-histone H3.
Increased apoptosis as measured by caspase-3 cleavage.
Increased antitumor activity when it was combined with both Cisplatin(HY-17394) or/and 5-FU(HY-90006) at 10 mg/kg.
Clinical Trial
CAS 号
性状

液体

颜色

Colorless to light yellow

运输条件

Shipping with dry ice.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料

纯度: 99.58%

COA (172 KB)

抗体抑制剂使用指南 (1152 KB)
参考文献

Depatuxizumab 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Depatuxizumab1471999-69-5ABT-806ABT806ABT 806EGFREpidermal growth factor receptorErbB-1HER1U87MGde2-7A431SCC15permeation of blood-brain barrierxenograft modelPDX modelanticancerInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Depatuxizumab
目录号：
HY-P99849
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z